Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

The Use of 5-Fluorodeoxy uridine (FUDR) as a Surgical Adjuvant in Carcinoma of the Stomach and Colorectum

Arch Surg. 1963;86(6):926-931. doi:10.1001/archsurg.1963.01310120044008.
Text Size: A A A
Published online


The fluorinated pyrimidines were first introduced as cancer chemotherapeutic drugs in 1957 by Heidelberger.3 The first of these, fluorouracil (FU), has received rather widespread usage and is now available on the market. Numerous other drugs in the group have been developed both by alterations of the pyrimidine structure and by using other members of the halogen family. Of these newer drugs, 5-fluorodeoxyuridine (FUDR) has shown the most promise and has been used most widely in clinical trials. Pharmacologic studies have shown that FUDR has about one half the toxicity of the parent FU; however, indications are that quantitatively it has only one half of the therapeutic effectiveness of the parent drug. In studies by Curreri and Ansfield1 the therapeutic effectiveness of this group of drugs against carcinoma of the alimentary tract, especially carcinoma of the large bowel, was demonstrated. The studies also indicated that FUDR is more effective


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.